Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
Willemze R, Jager U, Jehn U, Stryckmans P, Bury J, Suciu S, Solbu G, Zittoun R, Burghouts J, Löwenberg B, et al. Willemze R, et al. Among authors: suciu s. Eur J Cancer Clin Oncol. 1988 Nov;24(11):1721-5. doi: 10.1016/0277-5379(88)90073-9. Eur J Cancer Clin Oncol. 1988. PMID: 3061827
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC, Willemze R. Zittoun R, et al. Among authors: suciu s. J Clin Oncol. 1996 Jul;14(7):2150-9. doi: 10.1200/JCO.1996.14.7.2150. J Clin Oncol. 1996. PMID: 8683249 Free article. Clinical Trial.
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
De Witte T, Suciu S, Selleslag D, Labar B, Roozendaal K, Zittoun R, Ribeiro M, Kurstjens R, Hayat M, Dardenne M, Solbu G, Muus P. De Witte T, et al. Among authors: suciu s. Ann Hematol. 1996 Mar;72(3):119-24. doi: 10.1007/s002770050148. Ann Hematol. 1996. PMID: 8766252 Clinical Trial.
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, Berneman Z, Tjean M, Wijermans P, Dohner H, Jehn U, Labar B, Jaksic B, Dardenne M, Zittoun R. Willemze R, et al. Among authors: suciu s. Leukemia. 1997 Mar;11 Suppl 1:S24-7. Leukemia. 1997. PMID: 9130688 Clinical Trial.
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group.
Willemze R, van der Lely N, Zwierzina H, Suciu S, Solbu G, Gerhartz H, Labar B, Visani G, Peetermans ME, Jacobs A, et al. Willemze R, et al. Among authors: suciu s. Ann Hematol. 1992 Apr;64(4):173-80. doi: 10.1007/BF01696219. Ann Hematol. 1992. PMID: 1581405 Clinical Trial.
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Jehn U, Zittoun R, Suciu S, Fiere D, Haanen C, Peetermans M, Löwenberg B, Willemze R, Solbu G, Stryckmans P. Jehn U, et al. Among authors: suciu s. Haematol Blood Transfus. 1990;33:277-84. doi: 10.1007/978-3-642-74643-7_50. Haematol Blood Transfus. 1990. PMID: 1691132 Clinical Trial.
317 results